ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via ISI Web of Science (2)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Spiekerkoetter, E.
Right arrow Articles by Hoeper, M.M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Spiekerkoetter, E.
Right arrow Articles by Hoeper, M.M.
Eur Respir J 2002; 20:524-528
Copyright ©ERS Journals Ltd 2002

Effects of inhaled salbutamol in primary pulmonary hypertension

E. Spiekerkoetter, H. Fabel and M.M. Hoeper

Dept of Respiratory Medicine, Hannover Medical School, Hannover, Germany

CORRESPONDENCE: E. Spiekerkoetter, Dept of Respiratory Medicine, Hannover Medical School, 30625, Hannover, Germany. Fax: 49 5115323353. E-mail: edda.spiekerkoetter@t-online.de

Keywords: peripheral airway obstruction, primary pulmonary hypertension, salbutamol

Received: December 12, 2001
Accepted April 12, 2002


   Abstract
TOP
 Abstract
Methods and patients
 Results
 Discussion
 References
 
Although lung function is grossly normal in patients with primary pulmonary hypertension (PPH), mild-to-moderate peripheral airflow obstruction can be found in the majority of patients with this disease. Therefore, ß2-agonists may affect pulmonary function, blood gases and haemodynamics in patients with PPH.

Pulmonary function testing, blood gas measurements and right heart catheterisation was performed in 22 patients with PPH and the acute effects of inhaled salbutamol (0.2 mg) were measured.

Salbutamol caused an increase in the forced expiratory volume in one second (FEV1) from 2446±704 to 2550±776 mL. The mean expiratory flow at 50% of the vital capacity (MEF50) rose from 58±17 to 66±21% pred. The pulmonary artery pressures remained unchanged after inhalation of salbutamol, but the cardiac output increased significantly from 3.9±1.4 to 4.2±1.4 L·min–1 accompanied by significant increases in stroke volume and mixed venous oxygen saturation as well as a significant decrease in pulmonary vascular resistance. The arterial oxygen tension rose from 9±2.4 kPa (68±18 mmHg) at baseline to 9.7±2.8 kPa (73±21 mmHg) after inhalation of salbutamol, the alveolo-arterial oxygen gradient values improved from 6±2.5 kPa (45±19 mmHg) to 5.1±2.9 kPa (38±22 mmHg), respectively.

Inhaled salbutamol has beneficial acute effects on pulmonary function, blood gases and haemodynamics in patients with primary pulmonary hypertension.

Primary pulmonary hypertension (PPH) is caused by progressive obliteration of the pulmonary vascular bed leading to increasing pulmonary vascular resistance and eventually right heart failure 1. The cause of PPH is unknown even if recently discovered mutations in the bone morphogenetic receptor protein 2 (BMPR2) gene in patients with familial and sporadic disease may indicate a proliferative disorder of pulmonary vascular cells as a principal pathogenetic mechanism 2–4. Clinically, the diagnosis of PPH is one of exclusion, since other diseases causing secondary forms of pulmonary hypertension have to be ruled out 5. Therefore, one diagnostic criterion for the diagnosis of PPH is the exclusion of obstructive and restrictive pulmonary disease. Nevertheless, one common, but widely overlooked feature of PPH is mild-to-moderate peripheral airflow obstruction which can be detected in up to 80% of patients 6. To the present authors' knowledge there is only one study so far which has described airway responsiveness to inhaled ß2-agonists in children with pulmonary hypertension 7. It has not been previously investigated whether ß2-agonists may yield a clinical benefit for patients with PPH in terms of improved oxygenation and haemodynamics.

Therefore, the present authors initiated a pilot trial to test the acute effects of inhaled salbutamol, a selective ß2-agonist, on lung function, blood gases and haemodynamic variables in patients with PPH.


   Methods and patients
TOP
 Abstract
 Methods and patients
Results
 Discussion
 References
 
Patients
A total of 22 patients with PPH were studied. The diagnosis was established in accordance with the criteria recently formulated by a World Health Organization-sponsored meeting of experts in the field of pulmonary hypertension 5. The female:male ratio was 1:1 and the mean age was 45±21 yrs. Six out of the 22 patients were former smokers and none had a history of asthma.

The study protocol was approved by the institutional ethics committee and all patients gave informed consent.

Pulmonary function studies
Spirometric variables, lung volumes, flow/volume curves and single-breath diffusion capacity for carbon monoxide (corrected for haemoglobin levels) were obtained using a Ganshorn bodyplethysmograph (Ganshorn, Muennerstadt, Germany). All measurements were made in a seated position. After these measurements were completed, the patients received two puffs of 0.1 mg salbutamol (Sultanol®, GlaxoSmithKline GmbH & Co. KG, Munich, Germany) resulting in a total dose of 0.2 mg salbutamol. Spirometry and flow/volume curves were recorded again 10 min later, according to the present authors' guidelines to test reversibility of bronchoconstriction. Normal values were obtained from published references 8–10. The pulmonary function studies were performed 1–3 days before or after the haemodynamic assessments.

Haemodynamic assessment and blood gas measurements
All patients received a Swan-Ganz catheter and a femoral arterial line for diagnostic reasons unrelated to this study. During the investigation, the acute haemodynamic effects of aerosolised iloprost were usually assessed. Details of heart catheterisation and iloprost challenge have been described elsewhere 11–13. After drug challenge with iloprost, haemodynamic stability was documented at least 1 h later for a minimum period of 15 min before salbutamol was applied. A set of haemodynamics was recorded and blood was obtained from the pulmonary artery and the arterial line and immediately sent for blood gas measurement (ABL 520; Radiometer, Copenhagen, Denmark). The values obtained at this time were used as baseline values for the purposes of this study. Haemodynamic assessment and blood gas analyses were repeated 10 min after inhalation of 0.2 mg salbutamol, performed in a 30 seated position. The alveolo-arterial oxygen gradient (DA-a,O2) was calculated according to standard formula assuming a respiratory ratio (R) of 0.8 [14].

Statistical analysis
The results are given as mean±sd. Changes in lung function, blood gases and haemodynamics after inhalation of salbutamol compared to baseline were compared using a paired t-test. All tests were two-sided. The significance level was set at p<0.05. The correlation between independent variables was expressed by the correlation coefficient r.


   Results
TOP
 Abstract
 Methods and patients
 Results
Discussion
 References
 
Results of pulmonary function testing, blood gas analysis and heart catheterisation were available from all 22 patients. All studies were completed without complications and none of the patients experienced any side-effects from inhalation of salbutamol.

Pulmonary function testing
Lung volumes were normal in all patients. The total capacity was 93±13% pred. The corresponding results for vital capacity, functional residual capacity and residual volume were 90±12, 99±18 and 99±29%, respectively. The airway resistance was also normal in most patients (2.5±1.0 cmH2O·L·s–1; normal <3.5 cmH2O·L·s–1). The diffusion capacity for carbon monoxide was 65±17 % pred.

Although the forced expiratory volume in one second (FEV1) was normal in all of the patients in this study (2,446±704 mL, 89±12% pred), the flow/volume curves indicated considerable peripheral airflow obstruction (fig. 1Go). The peak expiratory flow (PEF) was 91±18 % pred but the mean expiratory flow rates at 50% and at 25% of the vital capacity (MEF50 and MEF25) were 58±17% pred and 45±14% pred, respectively. In eight patients, the MEF50 was <50% pred.



View larger version (17K):
[in this window]
[in a new window]
  		Fig. 1.— A representative picture of a flow/volume curve in a patient with primary pulmonary hypertension.

 
As shown in table 1Go, inhalation of salbutamol caused a mild but significant increase in FEV1, MEF50 and MEF25. There was no differences in the degree of peripheral airflow obstruction between former and never smokers.


View this table:
[in this window]
[in a new window]
  		Table 1— Results of pulmonary function testing in 22 patients with primary pulmonary hypertension before and after challenge with 0.2 mg salbutamol

 
Haemodynamics and blood gases
The results of haemodynamic assessment and blood gas measurements are shown in table 2Go. All patients suffered from severe pulmonary hypertension. After inhalation of salbutamol, the mean pulmonary artery pressure remained unchanged, but there was a significant increase in the cardiac output (fig. 2Go) accompanied by a significant increase in the stroke volume, and a slight rise in mixed venous saturation as well as a significant decrease in the pulmonary and systemic vascular resistance. The heart rate remained unchanged. In addition to the haemodynamic changes, inhalation of salbutamol caused a slight but statistically significant increase in the arterial oxygen tension.


View this table:
[in this window]
[in a new window]
  		Table 2— Results of right heart catheterisation and blood gas analysis in 22 patients with primary pulmonary hypertension before and after challenge with 0.2 mg salbutamol

 


View larger version (28K):
[in this window]
[in a new window]
  		Fig. 2.— Cardiac output in 22 patients with primary pulmonary hypertension before and after the inhalation of 0.2 mg salbutamol. •: individual variables; {circ}: mean±sd values.

 
The DA-a,O2 was 6.0±2.5 kPa (range 2.3–8.6 kPa) (45±19 mmHg (range 17–65 mmHg)) before and 5.1±2.9 kPa (range 0.9–8.3 kPa) (38±22 mmHg (range 7–63 mmHg)) after inhalation of salbutamol (p=0.004). Chronic hyperventilation was detected in all patients (carbon dioxide tension in arterial blood 4.0±0.4 kPa (30±3 mmHg)) but was not affected by salbutamol (table 2Go).

There was no correlation between the increase in cardiac output after salbutamol and the increase in cardiac output after acute challenge with iloprost (r=–0.04). In addition, there was no significant correlation between the haemodynamic response and the increase in expiratory flow rates or the arterial oxygen tension (data not shown).


   Discussion
TOP
 Abstract
 Methods and patients
 Results
 Discussion
References
 
This study confirms previous observations that peripheral airflow obstruction is a common finding in patients with PPH 6, 7, 15. Even if the FEV1 and airway resistance were normal or only mildly abnormal in the patients in this study, peripheral airflow obstruction was indicated by reductions in the MEF50 and MEF25 to 58±17% and 45±14% pred, respectively.

MEF50 has been used by many authors as a sensitive variable of peripheral airflow limitation in chronic obstructive pulmonary disease, in post-transplant patients with bronchiolitis obliterans or in occupational lung disease 16–.

A larger study on 171 patients with PPH corroborates the present data that peripheral airway obstruction is common in PPH 6. As in the patients here, the airway resistance as a whole did not differ significantly from healthy controls. This is plausible since an increase in airway resistance is more sensitive to obstruction of the larger airways than to small airways disease. Data from asthmatics show that even major obstruction of the peripheral airways can occur without recognisable increases of airway resistance 16.

It is possible that peripheral airflow limitation may contribute to exercise limitation and dyspnoea in patients with pulmonary hypertension. In a study on patients with congestive heart failure, Kidman et al. 20 showed a marked improvement of MEF25–75 in response to ipratropium bromide which resulted in a substantial increase in the maximum voluntary ventilation and a decrease in dyspnoea 20. Peripheral airflow obstruction may therefore contribute to work of breathing and exertional dyspnoea.

The cause of airflow obstruction in patients with PPH is unknown. There is limited data on a histomorphological correlate. Fernandes-Bonetti et al. 15 described pathological observations in necropsy and lung biopsy specimens of patients with PPH that showed signs of small airway disease. Other authors interpreted the findings of peripheral airflow obstruction as merely a result of the pathological changes present in the pulmonary vasculature 21.

Interestingly, the current study showed that peripheral obstruction in patients with PPH was partly, albeit incompletely reversible by applying ß2-agonists. This observation was first described in children with PPH by O'Hagan et al. 7.

It is possible that small airways are affected as innocent bystanders in patients with PPH. It is well known that endothelial dysfunction is a major pathogenetic factor in PPH 22–. Several studies suggest that abnormalities in endothelial function, including impaired production of prostacyclin and nitric oxide and excessive synthesis of endothelin eventually lead to vasoconstriction and subsequent vascular growth and remodelling. Yet all these mediators also have well-known effects on the bronchial system. Endothelin-1 mimics several features of asthma, including bronchospasm, airway remodelling, inflammatory cell recruitment and activation, oedema, mucus secretion and airway dysfunction 26. It possesses mitogenic effects on smooth muscle cells and fibroblasts and is a very potent bronchoconstrictor. Thus, the observed peripheral obstruction may be a result of some spill over of endothelin from the vasculature into the airway system. A recent study examining the effect of the endothelin receptor ET(A)/ET(B) antagonist bosentan on endothelin-induced bronchoconstriction showed that bosentan completely prevented the ET(B)-receptor agonist (IRL1620) induced bronchoconstriction 27.

In addition to the effects on airflow limitation, salbutamol had beneficial acute haemodynamic effects in the PPH patients in this study. The mean pulmonary artery pressure remained unchanged but the cardiac output rose significantly resulting in a decline in pulmonary vascular resistance. The increase in cardiac output was not caused by a chronotropic effect of salbutamol since the cardiac frequency remained unchanged. The stroke volume, in contrast, increased suggesting that salbutamol had a positive inotropic effect in the patients. Alternatively, inhalation of salbutamol may have caused some pulmonary vasodilation that was answered by a rise in the cardiac output. Pulmonary arterial smooth muscle cells carry ß2-receptors 28 so that some pulmonary vasodilatory effect of inhaled ß-agonists may well be expected. Conversely, Bristow et al. 29 have shown that the right ventricle, in patients with pulmonary hypertension, shows an altered expression of cellular receptors when compared to normal subjects and patients with left heart failure. One of the characteristic features of the right ventricle in patients with PPH is an increase in the expression of myocardial ß2-receptors 30. Therefore, it is quite possible that inhaled ß2-agonists may have a positive inotropic action in patients with PPH. There may be a dose-dependent dissociation of the inotropic and chronotropic actions of salbutamol. Zimmer et al. 31 showed, in studies with rat hearts, that certain doses of salbutamol produced an inotropic effect without any chronotropic effect.

In the group of patients present here with PPH, inhaled salbutamol had a positive effect on mixed venous oxygen saturation and arterial oxygenation. The current authors speculate that improvement of arterial oxygenation was presumably due to some positive effects of inhaled salbutamol on ventilation-perfusion matching although this study was not designed to address this question.

The increase in mixed venous oxygen saturation was primarily a result of the increase in cardiac output. It is striking, however, that the rise in cardiac output observed by thermodilution was considerably greater than the rise in mixed venous oxygen saturation. The reason for this observation might be an increase in oxygen consumption due to ß-adrenergic activation, as it has been shown in several studies 20, 32–.

The present study has several potential limitations. There was no control group and no blinding, so that any bias can not be fully excluded. The study was not designed to address long-term effects of inhaled ß2-agonists in PPH. It is unclear whether the demonstrated acute effects have any substantial meaning for long-term treatment.

In conclusion, this pilot trial on the effects of inhaled salbutamol in patients with primary pulmonary hypertension showed beneficial acute effects on lung function, blood gases and haemodynamics. Although it is unlikely that inhaled ß2-agonists will significantly affect the course of primary pulmonary hypertension, they deserve further evaluation as adjunctive treatment in this disease. However, since ß2-agonists may cause systemic side-effects such as hypokalaemia, tachycardia and arrhythmia among others, its routine use in patients with primary pulmonary hypertension cannot be recommended at this time.


   References
TOP
 Abstract
 Methods and patients
 Results
 Discussion
 References
 

  1. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997;336:111–117.[Free Full Text]
  2. Deng Z, Morse JH, Slager S, et al. Familial primary pulmonary hypertension (Gene PPH-1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 2000;67:737–744.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  3. Machado RD, Pauciulo MW, Thomson JR, et al. BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am J Hum Genet 2001;68:92–102.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  4. Thomson JR, Machado RD, Pauciulo MW, et al. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-ß family. J Med Genet 2000;37:741–745.[Abstract/Free Full Text]
  5. Rich S. Summary from the world symposium on primary pulmonary hypertension 1998http://www.who.int/ncd/cvd7pph.html. Date last updated: July 4 2001. Date last accessed: December 11 2001.
  6. Meyer FJ, Ewert R, Hoeper MM, et al. Peripheral airway obstruction in Primary Pulmonary Hypertension. Thorax 2002;57:473–476.[Abstract/Free Full Text]
  7. O'Hagen AR, Stilwell PC, Arroliga A. Airway resposiveness to inhaled albuterol in patients with pulmonary hypertension. Clin Pediatr 1999;38:27–33.[Abstract/Free Full Text]
  8. Bass H. The flow volume loop: normal standards and abnormalities in chronic obstructive pulmonary disease. Chest 1973;63:171–177.[Abstract/Free Full Text]
  9. Steel Ecfca. Bull Europ Physiopath Resp 1983;19:7–21.[ISI][Medline] [Order article via Infotrieve]
  10. Miller A, Thronton JC, Warshaw R, Anderson H, Teirstein AS, Selikoff IJ. Single breath diffusion capacity in a representative sample of the population of Michigan, a large industrial state: predicted values, lower limits of normal, and frequencies of abnormality in smoking history. Am Rev Respir Dis 1983;127:270–277.[ISI][Medline] [Order article via Infotrieve]
  11. Hoeper MM, Maier RM, Tongers J, et al. Determination of cardiac output by the Fick method, thermodilution and acetylene rebreathing in pulmonary hypertension. Am J Resp Crit Care Med 1999;160:535–541.[Abstract/Free Full Text]
  12. Hoeper MM, Olschewski H, Ghofrani HA, et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerolized iloprost in primary pulmonary hypertension. J Am Coll Cardiol 2000;35:176–182.[Abstract/Free Full Text]
  13. Hoeper MM, Schwarze M, Ehlerding S, et al. Long-term treatment of primary pulmonary hypertension with aerolized iloprost, a prostacyclin analogue. N Engl J Med 2000;342:1866–1870.[Abstract/Free Full Text]
  14. Wassermann K, Hansen JE, Sue DY, Whipp BJ, Casaburi R. Principles of exercise testing and interpretation. 2nd ednMalvern, PA, USA, Lea and Febinger, 1994; pp. 456–457.
  15. Fernandes-Bonetti P, Lupi-Herrera E, Martinez-Guerra ML, Barrios R, Seoane M, Sandoval J. Peripheral Airways Obstruction in Idiopathic Pulmonary Artery Hypertension (Primary). Chest 1983;83:732–738.[Abstract/Free Full Text]
  16. Cherniack R. Physiologic diagnosis and function in asthma. Clin Chest Med 1995;16:567–581.[ISI][Medline] [Order article via Infotrieve]
  17. Pilette C, Godding V, Kiss R, et al. Reduced epithelial expression of secretory component in small airways correlates with airflow obstruction in chronic obstructive pulmonary disease. Am J Resp Crit Care Med 2001;163:185–194.[Abstract/Free Full Text]
  18. Brand P, App EM, Meyer T, et al. Aerosol bolus dispersion in patients with bronchiolits obliterans after heart-lung and double-lung transplantation. J Aerosol Med 1998;11:41–53.[ISI][Medline] [Order article via Infotrieve]
  19. Wolf C, Pirich C, Valic E, Waldhoer T. Pulmonary function and symptoms of welders. Int Arch Occup Environ Health 1997;69:350–353.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  20. Kindman LA, Vagelos RH, Willson K, Prikazky L, Fowler M. Abnormalities of pulmonary function in patients with congestive heart failure, and reversal with Ipratropium Bromide. Am J Cardiol 1994;73:258–262.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  21. Scharff SM, Feldman NT, Graboys TB, Wellman JJ. Restrictive ventilatory defect in a patient with primary pulmonary hypertension. Am Rev Resp Dis 1978;118:409–413.[ISI][Medline] [Order article via Infotrieve]
  22. Loscalzo J. Endothelial dysfunction in pulmonary hypertension. NEJM 1992;327:117–119.[ISI][Medline] [Order article via Infotrieve]
  23. Christman B, McPherson CD, Newman JH, et al. An Imbalance between the excretion of thromboxane and prostacylin metabolites in pulmonary hypertension. NEJM 1992;327:70–75.[Abstract]
  24. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. NEJM 1995;333:214–221.[Abstract/Free Full Text]
  25. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. NEJM 1993;328:1732–1739.[Abstract/Free Full Text]
  26. Hay DWP. Annual Scientific Meeting 1997. Putative Mediator Role of Endothelin-1 in Asthma and other lung diseases. Clin Exper Pharm Physiol 1999;26:168–171.
  27. Martin C, Held HD, Uhlig S. Differential effects of the mixed ET(A)/ET(B)-receptor antagonist bosentan on endothelin-induced bronchoconstriction, vasoconstriction and prostacyclin release. Naunyn Schmiedebergs Arch Pharmacol 2000;362:128–136.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  28. Bevan RD. Influence of adrenergic innervation on vascular growth and mature characteristics. Am Rev Resp Dis 1989;140:1478–1482.[ISI][Medline] [Order article via Infotrieve]
  29. Bristow MJ, Lowes BD, Abraham WT, et al. The pressure-overloaded right ventricle in pulmonary hypertension. Chest 1998;114:101S–106S.[ISI][Medline] [Order article via Infotrieve]
  30. Lowes BD, Minobe W, Abraham WT, et al. Changes in gene expression in the intact human heart. Downregulation of alpha-myosin heavy chain in hypertrophied, failing ventricular myocardium. J Clin Invest 1997;100:2315–2324.[ISI][Medline] [Order article via Infotrieve]
  31. Zimmer G, Dahinten A, Fitzner A, et al. Beta-agonistic bronchodilators. Comparison of dose-response in working rat hearts. Chest 2000;117:519–529.[Abstract/Free Full Text]
  32. Uren NG, Davies SW, Jordan SL, Lipkin DP. Inhaled bronchodilators increase maximum oxygen consumption in chronic left ventricular failure. Eur Heart J 1993;14:744–750.[Abstract/Free Full Text]
  33. Bailey J, Colahan P, Kubilis P, Pablo L. Effect of inhaled beta 2 adrenoceptor agonist, albuterol sulphate, on performance of horses. Equine Vet J Suppl 1999;30:575–580.[Medline] [Order article via Infotrieve]
  34. Newth CJ, Amsler B, Richardson BP, Hammer J. The effects of bronchodilators on spontaneous ventilation and oxygen consumption in rhesus monkeys. Pediatr Res 1997;42:157–162.[ISI][Medline] [Order article via Infotrieve]




This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via ISI Web of Science (2)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Spiekerkoetter, E.
Right arrow Articles by Hoeper, M.M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Spiekerkoetter, E.
Right arrow Articles by Hoeper, M.M.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS